Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 5
Submit an article Journal homepage
136
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond

Alfonso Quintás-CardamaTCR Therapeutics, Cambridge, MA, USACorrespondence[email protected]
Pages 1346-1348 | Received 20 Aug 2018, Accepted 30 Sep 2018, Published online: 16 Jan 2019

References

  • Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
  • Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
  • Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). J Clin Oncol. 2016. 34(15):7002–7002.
  • DeAngelo DJ, Ghobadi A, Park JH, et al. Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). 32nd Annu SITC Meet Abstr B. 2017;P217:305–306.
  • Poh A. JCAR015 in all: a root-cause investigation. Cancer Discov. 2018;8:4–5.
  • Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459.
  • Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404–1419.
  • Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet [Internet]. 2015;385:517–528
  • Gardner RA, Finney O, Annesley C, et al. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322–3331.
  • Turtle CJ, Hanafi L, Berger C, et al. CD19 CAR – T cells of defined CD4 +: CD8 + composition in adult B cell ALL patients. J Clin Invest. 2016;1:1–16.
  • Shah BD, Oluwole OO, Baer MR, et al. Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: a study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). J Clin Oncol. 2018;36:7006.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.